Results 51 to 60 of about 24,588 (279)

Successful treatment of refractory status asthmaticus with omalizumab: a case report [PDF]

, 2021
Jan Benes, Roman Škulec, Dalibor Jílek, Ondřej Fibigr, Vladimír Černý   +4 more
openalex   +1 more source

Association of autoimmune diseases with biologic agents targeting type 2 immunity: An observational study using a claims database

Rheumatology &Autoimmunity, EarlyView.
This observational study assessed the association between anti‐type 2 biologic agents and the occurrence of autoimmune diseases using a large real‐world claims database. Anti‐IL‐5 and anti‐IgE therapies were associated with an increased occurrence of autoimmune diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE ...
Shoichiro Inokuchi
wiley   +1 more source

Real-World Observational Study on the Characteristics and Treatment Patterns of Allergic Asthma Patients Receiving Omalizumab in Canada

Patient Preference and Adherence, 2020
Jason K Lee,1 Suvina Amin,2 Michelle Erdmann,3 Atif Kukaswadia,4 Jelena Ivanovic,5 Aren Fischer,4 Alain Gendron6 1Clinical Immunology and Allergy, Internal Medicine, Evidence Based Medical Educator Inc.
Lee JK, Amin S, Erdmann M, Kukaswadia A, Ivanovic J, Fischer A, Gendron A   +6 more
doaj  

Serum free IgE guided dose reduction of omalizumab: a case report

Allergy, Asthma & Clinical Immunology, 2017
Background Omalizumab is a human IgG1 antibody against IgE used as a therapy for sever asthmatic patients with asthma. According to the guidelines of the Global Initiative for Asthma, omalizumab is an add-on drug at treatment step 5 that is used for ...
Yasuhiro Gon, Reiko Ito, Shuichiro Maruoka, Kenji Mizumura, Yutaka Kozu, Hisato Hiranuma, Yuko Iida, Sotaro Shikano, Shu Hashimoto   +8 more
doaj   +1 more source

Omalizumab for successful chemotherapy desensitisation: What we know so far

Clinical and Translational Allergy, 2021
Background Hypersensitivity reactions induced by chemotherapeutic drugs may influence the course of the oncologic disease by preventing doctors from prescribing first‐line therapy.
Roxana Silvia Bumbacea, Selda Ali, Sabina Loredana Corcea, Luiza Spiru, Cornelia Nitipir, Victor Strambu, Dragos Bumbacea   +6 more
doaj   +1 more source

Dupilumab for bullous pemphigoid with intractable pruritus [PDF]

, 2019
Bullous pemphigoid (BP) is an autoimmune blistering disorder that predominantly affects the elderly. Treatment regimens typically include topical and systemic immunosuppressive medications.
Eichenfield, Dawn Z, Orme, Charisse M, Seidman, Jason S   +2 more
core  

Chinese Guidelines for Diagnosis and Treatment of Chronic Rhinosinusitis (2024)

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Chronic rhinosinusitis (CRS), a complex inflammatory disease with heterogeneous pathogenesis, demands evolving evidence‐based strategies. Since the 2018 Chinese guidelines and EPOS2020, international advances in CRS immunopathology and biologics have revolutionized therapeutic approaches, particularly through phenotype–endotype classification ...
Subspecialty Group of Rhinology, Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery, Subspecialty Group of Rhinology, Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association   +4 more
wiley   +1 more source

Omalizumab is ineffective in regulating proasthmatic serum cytokine and chemokine levels in nonresponders with high BMI

Journal of Allergy and Clinical Immunology: Global
Background: Omalizumab provides clinical benefits to a fraction of patients with asthma. It remains unclear why some patients do not respond to omalizumab therapy.
Agnes Yang, BS, Chao Gu, PhD, Katherine Upchurch, PhD, Adrien Caffiers, MS, Mark Millard, MD, Laurie Baert, PhD, HyeMee Joo, PhD, SangKon Oh, PhD   +7 more
doaj   +1 more source

Omalizumab: Clinical Use for the Management of Asthma

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2012
Omalizumab, a humanized monoclonal antibody that binds circulating IgE antibody, is a treatment option for patients with moderate to severe allergic asthma whose asthma is poorly controlled with inhaled corticosteroids and inhaled long-acting β 2 agonist
Neil C. Thomson, Rekha Chaudhuri
doaj   +1 more source

Omalizumab for management of refractory urticaria: Experience of a tertiary care centre in Eastern India

Indian Journal of Dermatology, 2018
Aim: To study the effects of omalizumab in chronic spontaneous urticaria in Indian patients. Setting and Design: The study was conducted in a tertiary care centre and it was retrospective and descriptive in nature.
Shekhar Neema, Manas Chatterjee
doaj   +1 more source